DMAC News and Press, DiaMedica Therapeutics Inc. From 05/07/20

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2020 financial results will be released after the markets close on Wednesday, May 13 th . DiaMedica will host a live conference call on Thursday, May 14 th at 7:00 AM Central Time to discuss its business update...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled “Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease ...

DiaMedica Therapeutics Inc. (DMAC) Q4 2019 Results Earnings Conference Call March 24, 2020, 8:00 am ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital ...

DiaMedica Therapeutics (NASDAQ: DMAC ): FY GAAP EPS of -$0.89 beats by $0.04 . More news on: DiaMedica Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment; Data Readout Expected in Q2 2020 Phase II Study of DM199 in Chronic Kidney Disease Ongoing; Steps Being Taken to Mitigate Potential Impact of COVID-19 Raised $8.5 Million in Gross Proceeds in Pu...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its fourth quarter 2019 financial results will be released after the markets close on Monday, March 23 rd . DiaMedica will host a live conference call on Tuesday, March 24 th at 7:00 AM Central Time to discuss its business updat...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will participate at the 32 nd Annual ROTH Conference The conference will be held from March 15-17, 2020 at The Ritz Carlton, Laguna Niguel, California. Mr. Pauls will also...

  DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced the closing of its previously announced underwritten public offering of an aggregate of 2,125,000 shares of its voting common shares at a public offering price of $4.00 per share. ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share. All of the common shares are being offered by DiaMedica....

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...